Navigation Links
Nutra Pharma Patent and Trademarks Published in India
Date:3/25/2013

CORAL SPRINGS, Fla., March 25, 2013 /PRNewswire/ -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received notification that their patent and trademarks for its Nyloxin™ line of pain relievers have been published in India's Official Journal. This allows for patent and brand protection, leading to eventual sales through Indian distributors.

"The patent and trademark publications in India represents one of the more significant international market opportunities for Nyloxin," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Now that we have patent protection to protect our formulas and trademark protection to defend the brand we can work to create sales and distribution in India. With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India represents a potentially significant customer base for Nyloxin," he concluded.

According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.

The patent, "Use of Cobratoxin as an Analgesic," was published in the Official Journal No.: 09/2013 of the Indian Patent Office (IPO) on March 1, 2013. The Trademarks for Nyloxin™ are registered in India under Class 5, which represents a Pharmaceutical or a dietetic substances adapted for medical use.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.  Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of Nutra Pharma's patent and trademarks in India should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:

Nutra Pharma Corp.

Nina Goldstein

877-895-5647

IR@nutrapharma.com

 


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aveka Nutra Processing proudly begins producing products from Z Trim Holdings, Inc.
2. Musculoskeletal Network Features Update on Nutraceuticals for Osteoarthritis
3. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
4. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
5. Pharmacy Automation Systems Market is Expected to Reach USD 7.8 Billion by 2018: Transparency Market Research
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
7. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
8. Pharmaceutical Pricing and Health Outcomes Top Trending News This Week from HealthEconomics.Com
9. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
10. PharmAthene Reports Year-End 2012 Financial And Operational Results
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... , ... March 22, 2017...Council for Agricultural Science and Technology, Ames, Iowa. ... innovation in smart, sustainable ways. Humans depend on plants for food, feed, fiber, and ... This paper is the first in a series that connects science and technology to ...
(Date:3/22/2017)... Mass. , March 22, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... RXi,s Chief Business Officer, will present at the ... forum will provide a platform to present to ... institutes, leading pharmaceutical and biotech companies as well ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... with the ability of endogenous hormones to regulate homeostasis via their cognate ... (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC exposure ...
(Date:3/20/2017)... ... March 20, 2017 , ... Existing ... preparation methods in order to reduce the impact on instrumentation. ICP-MS is a ... of elemental analysis. , This presentation will discuss the pros and cons ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
Breaking Biology News(10 mins):